How ONL used iNebula to accelerate its Phase 2 trial
ONL discuss their collaboration on a recent Phase 2 rhegmatogenous retinal detachment (RRD) program. The panelists discuss the importance of partnering with a reading center that offers Voxeleron’s iNebula platform – in particular for its real-time access to the image data as well as its AI-enabled endpoints.
- Connie Change: Chief Operating Officer at ONL
- Sally Tucker: President, Global Services at Lexitas Pharma Services
- Daniel Russakoff: Chief Technology Officer at Voxeleron